JP2023507387A5 - - Google Patents

Info

Publication number
JP2023507387A5
JP2023507387A5 JP2022537270A JP2022537270A JP2023507387A5 JP 2023507387 A5 JP2023507387 A5 JP 2023507387A5 JP 2022537270 A JP2022537270 A JP 2022537270A JP 2022537270 A JP2022537270 A JP 2022537270A JP 2023507387 A5 JP2023507387 A5 JP 2023507387A5
Authority
JP
Japan
Prior art keywords
combination
liver disease
pharmaceuticals
disorder
pharmaceuticals according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022537270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507387A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/066079 external-priority patent/WO2021127483A1/en
Publication of JP2023507387A publication Critical patent/JP2023507387A/ja
Publication of JP2023507387A5 publication Critical patent/JP2023507387A5/ja
Pending legal-status Critical Current

Links

JP2022537270A 2019-12-20 2020-12-18 インテグリン阻害剤を使用する肝疾患の治療の組み合わせ Pending JP2023507387A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951615P 2019-12-20 2019-12-20
US62/951,615 2019-12-20
PCT/US2020/066079 WO2021127483A1 (en) 2019-12-20 2020-12-18 Combination treatment of liver diseases using integrin inhibitors

Publications (2)

Publication Number Publication Date
JP2023507387A JP2023507387A (ja) 2023-02-22
JP2023507387A5 true JP2023507387A5 (enExample) 2023-10-26

Family

ID=74186956

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022537270A Pending JP2023507387A (ja) 2019-12-20 2020-12-18 インテグリン阻害剤を使用する肝疾患の治療の組み合わせ

Country Status (11)

Country Link
US (1) US20230055657A1 (enExample)
EP (1) EP4076455A1 (enExample)
JP (1) JP2023507387A (enExample)
KR (1) KR20220121838A (enExample)
CN (1) CN114929219A (enExample)
AR (1) AR120859A1 (enExample)
AU (1) AU2020405182B2 (enExample)
CA (1) CA3165000A1 (enExample)
IL (1) IL293895A (enExample)
TW (1) TW202135812A (enExample)
WO (1) WO2021127483A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220220206A1 (en) * 2019-05-20 2022-07-14 Mayo Foundation For Medical Education And Research Treating chronic liver disease
US20230060422A1 (en) * 2019-12-20 2023-03-02 Novartis Ag Combination treatment of liver diseases using integrin inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP3509590A4 (en) * 2016-09-07 2020-12-02 Pliant Therapeutics, Inc. N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE
RU2019110780A (ru) * 2016-09-14 2020-10-15 Новартис Аг Комбинация агонистов fxr
TWI841573B (zh) * 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
CN118852054A (zh) * 2019-02-06 2024-10-29 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途

Similar Documents

Publication Publication Date Title
CN113490493B (zh) 治疗脂肪性肝病和/或脂肪性肝炎的方法
WO2013142369A1 (en) Treatment of pulmonary hypertension with leukotriene inhibitors
HRP20211032T1 (hr) Postupci za uporabu agonista fxr
JP2023507387A5 (enExample)
JP6363104B2 (ja) 15−ohepaを含む組成物および同組成物を使用する方法
JP2014518268A5 (enExample)
JP2009530413A5 (enExample)
CN105189438A (zh) 用于治疗纤维化的经取代的芳族化合物及相关方法
JP2018030855A5 (enExample)
KR20180115700A (ko) Fxr 효능제를 사용하는 방법
JP2018507914A5 (enExample)
RU2019113150A (ru) Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения
JP2013526520A5 (enExample)
HRP20141048T1 (hr) Spojevi, pripravci i metode
JP2018531289A5 (enExample)
JP2022522486A5 (enExample)
RU2019110780A (ru) Комбинация агонистов fxr
JP2019536812A5 (enExample)
JP5941258B2 (ja) 他の薬剤と組合せた(r,r)−ホルモテロール
JP2011521992A (ja) アトルバスタチン4−(ニトロキシ)ブチルエステルおよび脂質低下剤を含む組成物
JP2022515272A5 (enExample)
JP2002534477A5 (enExample)
JP2007525533A5 (enExample)
JP2013518061A5 (enExample)
CN109310669B (zh) 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途